-
Emphysema Market Analysis Reveals Promising Growth Opportunities and Trends During the Forecast Period (2025-2034) | DelveInsight
21 Oct 2025 22:44 GMT
… (Beam Therapeutics), itepekimab (Regeneron Pharmaceuticals/Sanofi), depemokimab ( … (Beam Therapeutics), itepekimab (Regeneron Pharmaceuticals/Sanofi), depemokimab … GlaxoSmithKline, Verona Pharma plc, Regeneron Pharmaceuticals, Sanofi, MedImmune LLC, …
-
EMA Backs New Checkpoint Inhibitor for High-Risk Skin Cancer
21 Oct 2025 11:44 GMT
… favorable opinion for Libtayo (cemiplimab, Regeneron Pharmaceuticals) as adjuvant treatment for adults …
-
Lisa Jarvis: A new gene therapy for a rare form of congenital deafness looks promising
19 Oct 2025 16:53 GMT
… a gene therapy developed by Regeneron Pharmaceuticals Inc. when she was 10 …
-
<![CDATA[Incidence of Second Primary Tumors Is Similar Between Adjuvant Cemiplimab and Placebo in High-Risk CSCC]]>
18 Oct 2025 18:59 GMT
… , Decibel Therapeutics, Erasca, Marck, and Regeneron Pharmaceuticals; and having uncompensated relationships with … Eisai, GSK, Merck, and Regeneron Pharmaceuticals.
References
Rischin D, Porceddu S …
-
FDA Unveils First 9 Picks for Pilot Program Speeding Up Review of ‘National Priority’ Products
17 Oct 2025 22:13 GMT
… medicines more affordable and accessible.
Regeneron Pharmaceuticals’ DB-OTO is a gene …
-
White House announces deal to lower IVF drug prices
17 Oct 2025 22:12 GMT
… nicotine vaping addiction; DB-OTO (Regeneron Pharmaceuticals) for deafness; cenegermin-bkbj (Dompé …
-
<![CDATA[Sevabertinib Monotherapy Shows Robust Response in HER2-Mutant NSCLC]]>
17 Oct 2025 20:44 GMT
… , Janssen Biotech, Merck KGaA, Novartis, Regeneron Pharmaceuticals, and Spectrum Pharmaceuticals.
REFERENCES:
1 …
-
Toddler born deaf hears for the first time after groundbreaking gene therapy
17 Oct 2025 19:42 GMT
… DB-OTO, was developed by Regeneron Pharmaceuticals, a biotech company based in …
-
<![CDATA[Cemiplimab Moves Closer to EU Approval in Adjuvant CSCC]]>
17 Oct 2025 15:18 GMT
Regeneron Pharmaceuticals’ PD-1 inhibitor Libtayo (cemiplimab … surgery and radiation. News release. Regeneron Pharmaceuticals. Published October 17, 2025. Accessed … Surgery and Radiation. News release. Regeneron Pharmaceuticals. Published October 8, 2025. …
-
Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
17 Oct 2025 11:30 GMT
… . 17, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced … also report side effects to Regeneron Pharmaceuticals at 1-877-542-8296 … and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company …
About
© 1995-2025